PROVETOP
Request a Quote

Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein

Catalog No: HLAA0201-HB012

Species
Human
Expression System
HEK293
Tag
His, Avi

Product overview

Recombinant Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and CLAVEEVSL peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &CLAVEEVSL).

Product Details

Molecular Aliases
NPM1-CLAV (CLAVEEVSL); NPM1-CLAV; CLAVEEVSL;
Protein Length
Gly25-Thr305
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 50.4 kDa. Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
HLAA0201-HB012 Bis-Tris-PAGE-white result

Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
HLAA0201-HB012 SEC-HPLC result

The purity of Biotinylated Human HLA-A*02:01&B2M&NPM1-CLAV (CLAVEEVSL) Monomer is greater than 95% as determined by SEC-HPLC.

Background

The nucleophosmin (NPM1) mutant protein, a leukemia-associated antigen characterized by its leukemia-restricted expression and immunogenic potential, has emerged as a promising therapeutic target for acute myeloid leukemia (AML) immunotherapy. Among its immunogenic epitopes, the CLAVEEVSL peptide derived from the full C-terminal region of the NPM1-mutated isoform demonstrates potent immunogenicity, making it a prime candidate for T cell-based immunotherapies.

References

  1. [1] Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. DOI: 10.18632/oncotarget.26617
  2. [2] Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. DOI: 10.3390/ijms22179159

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support